遗传性与获得性出血性疾病中的免疫并发症及其管理
综述讨论凝血因子缺乏患者中抗药抗体(ADA)和自身抗体导致的免疫并发症,涵盖血友病抑制物、获得性血友病及针对血管性血友病因子(VWF)的抗体。管理策略包括免疫耐受诱导(ITI)、免疫抑制治疗(IST)和 bypass 抗体的非因子疗法(NFT),并探讨了临床前阶段的细胞免疫治疗、基因治疗和口服抗原给药。
要点
- 抗药抗体(ADA)可中和凝血因子VIII或IX,显著复杂化血友病替代治疗。
- 针对因子VIII的自身抗体导致获得性血友病,针对VWF的抗体虽罕见但可在其他凝血因子缺乏治疗中出现。
- 管理策略包括免疫耐受诱导(ITI)、免疫抑制治疗(IST)和绕过抗体的非因子疗法(NFT)。
核心结论
- ITI可作为重要原理验证,表明通过反复抗原给药可在人类中实现抗原特异性免疫耐受,即使没有免疫抑制。
- 针对遗传性和自身免疫性出血性疾病,免疫治疗或替代疗法的选择及具体方案标准在文中有所解释。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 针对因子VIII或IX的中和抗体显著复杂化血友病治疗。
- 针对因子VIII的自身抗体导致获得性血友病。
- 抗体形成可发生在其他凝血因子缺乏的治疗中,例如针对血管性血友病因子(VWF)。
- 管理免疫反应的主要策略包括:临床免疫耐受诱导(ITI)方案、免疫抑制治疗(IST)、以及开发可改善止血同时完全绕过抗凝血因子抗体的药物(部分非因子疗法/NFT为抗体类,但与传统免疫治疗不同,因其不靶向免疫系统)。
关键数值与推荐
- 原文未报告具体推荐条款或数值标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Disorders of coagulation, resulting in serious risks for bleeding, may be caused by autoantibody formation or by mutations in genes encoding coagulation factors. In the latter case, antidrug antibodies (ADAs) may form against the clotting factor protein drugs used in replacement therapy, as is well documented in the treatment of the X-linked disease hemophilia. Such neutralizing antibodies against factors VIII or IX substantially complicate treatment. Autoantibody formation against factor VIII leads to acquired hemophilia. Although rare, antibody formation may occur in the treatment of other clotting factor deficiencies (eg, against von Willebrand factor [VWF]). The main strategies that have emerged to address these immune responses include (1) clinical immune tolerance induction (ITI) protocols; (2) immune suppression therapies (ISTs); and (3) the development of drugs that can improve hemostasis while bypassing the antibodies against coagulation factors altogether (some of these nonfactor therapies/NFTs are antibody-based, but they are distinct from traditional immunotherapy as they do not target the immune system). Choice of immune or alternative therapy and criteria for selection of a specific regimen for inherited and autoimmune bleeding disorders are explained. ITI serves as an important proof of principle that antigen-specific immune tolerance can be achieved in humans through repeated antigen administration, even in the absence of immune suppression. Finally, novel immunotherapy approaches that are still in the preclinical phase, such as cellular (for instance, regulatory T cell [Treg]) immunotherapies, gene therapy, and oral antigen administration, are discussed.
引用
- Arruda VR, Lillicrap D, Herzog RW, et al. Immune complications and their management in inherited and acquired bleeding disorders. Blood. 2022. PMID: 35793465. doi:10.1182/blood.2022016530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。